The study aimed to investigate new technologies for diagnosing and prognosing cutaneous melanoma. Researchers noticed that advanced genomic and imaging tests significantly improve melanoma diagnosis and prognosis, guiding more effective clinical decisions. Cutaneous melanoma (CM) is among the most prevalent malignancies in the United States, with its incidence on the rise. This cancer […]
Understanding Mental Health in CRC Survivorship
The study aimed to investigate the lived mental health experiences of patients with colorectal cancer across the entire care continuum. Researchers noted that integrating mental health support could enhance patient well-being throughout CRC care. Colorectal cancer (CRC) diagnosis is linked to significant physical stressors such as surgery, chemotherapy, radiation, and often the creation […]
Liver Cancer Burden and Risks in the U.S. Over Time
The study aimed to investigate the trends, risk factors, and outcomes of liver cancer in the US from 1990 to 2019. The study found a significant rise in U.S. liver cancer, driven by preventable factors, needing urgent public health action. Liver cancer represents a significant public health concern, often developing in the context […]
AI-CDSS Tool Enhances BC Recurrence Prediction
The study aimed to develop and validate a machine learning model for a web-based AI-CDSS application to improve BC recurrence prediction. The AI-CDSS tool, enhanced by ChatGPT, showed promise in predicting BC recurrence but needs broader validation. Breast cancer (BC) is a major global health issue, highlighting the need for improved methods of […]
Universal Genetic Testing in Newly Diagnosed Invasive Breast Cancer
The study aimed to evaluate the prevalence of germline pathogenic variants in breast cancer susceptibility genes among newly diagnosed women. Researchers found 7.3% GPV prevalence, with 5.3% B1B2P2 positive; one-third were eligible for PARP inhibitors. Between 5% and 10% of breast cancer are hereditary, linked to inherited genetic mutations. Traditional genetic testing methods […]
Clinicopathological Value of Gut Microbial Subtypes in CRC
The study aimed to investigate the development of gut microbial subtypes and their potential as diagnostic targets for CRC. Researchers noticed that gut microbial subtypes show distinct bacterial profiles, which may aid in the early diagnosis of CRC. Gut bacteria are increasingly recognized as being related to colorectal cancer (CRC) and its clinicopathologic […]
Advertisement
MOST RECENT
Targeting IL-33 Boosts Anti-PD-L1 Therapy by Altering TME
The study aimed to examine whether IL-33 hinders anti-PD-L1 efficacy and explored dual-targeting therapeutic potential. Results showed that blocking IL-33/ST2 enhances anti-PD-L1 efficacy, offering a new cancer treatment strategy. The immunosuppressive tumor microenvironment (TME) poses a major obstacle to the success of immune checkpoint inhibitors, such as those targeting the PD-1/PD-L1 pathway, in […]
En Bloc Resection in NSCLC Feasibility and Outcomes
The study aimed to evaluate the safety and efficacy of en bloc surgery vs. conventional surgery for resectable NSCLC. Researchers revealed that en bloc surgery is feasible for patients with potentially N-positive NSCLC. Non-small-cell lung cancer (NSCLC) is a common type of lung cancer often treated with surgical resection. While conventional surgery involves […]
Autophagy-Related Genes in Tongue Cancer Affected by PP
The study aimed to investigate the anti-tumor mechanisms of PP in TSCC using network pharmacology and in vitro experiments. The findings suggested that PP may inhibit TSCC by activating autophagy, targeting MAPK3 and PSEN1. Tongue squamous cell carcinoma (TSCC) is the most common type of head and neck squamous cell carcinoma (HNSCC), accounting […]
Enhancing Communication in Gynecologic Cancer Survivorship
The study aimed to explore the experiences of sexual distress and communication regarding sexual health in gynecologic cancer survivors. Gynecologic cancer survivors need better communication and resources, with participants seeking more dialogue and provider training. The increasing prevalence of gynecologic cancer survivorship brings with it a significant impact on survivors’ quality of life […]
Advertisement
MOST RECENT
Popular With Peers
SKB264 + KL-A167 Shows Promise in NSCLC: OptiTROP-Lung01
The study aimed to assess the efficacy and safety of combining SKB264 with KL-A167 in patients with advanced NSCLC. Researchers observed that SKB264 + KL-A167 demonstrated promising efficacy and safety; further investigation is ongoing. Sacituzumab Tirumotecan (SKB264/MK-2870) is a TROP2 ADC developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase […]
Efficacy of Fulzerasib/Cetuximab in KRAS G12C NSCLC
The phase 1 & 2 trial aimed to investigate the efficacy and safety of combining fulzerasib, with cetuximab as front-line treatment for patients with NSCLC. The primary objective was to evaluate fulzerasib with cetuximab in untreated advanced NSCLC with KRAS G12C mutation. Researchers noticed promising efficacy and safety of fulzerasib + cetuximab; further […]
TN+ SPA or RIB Therapies: Safe & Tolerated
The phase I trial aimed to assess TN’s safety and efficacy combined with SPA or RIB in advanced solid tumor patients. The results demonstrated that TN combined with SPA or RIB was well-tolerated at recommended doses, with safety profiles consistent with individual agents. Omar Saavedra Santa Gadea and the team spearheaded the study […]
VenDd Elicits Durable MRD Negativity in Myeloma
The interventional phase 2 trial aimed to compare MRD in VenDd vs. DVd RRMM. The results demonstrated that VenDd was superior MRD clearance and extended PFS in t(11;14)-positive RRMM compared to DVd. Multiple myeloma shows hematologic malignancies that involve abnormal cell proliferation in the bone marrow—the combination of venetoclax (Ven), a potent BCL-2 […]
Combined Efficacy of Tucatinib and Trastuzumab for HER2-Positive MBTC
The phase II trial aimed to evaluate the combined efficacy and safety of TUC and Tras in HER2-altered solid tumor pts. The primary endpoint was cORR. Secondary endpoints include OS, DCR, DOR, PFS, and safety. The study found that combined therapy was well-tolerated and showed promising antitumor activity in pts. Biliary tract cancer […]
Amivantamab Shows Efficacy In Pts With Advanced NSCLC
The phase 1 CHRYSALIS study evaluated amivantamab (ami) for treating advanced non-small cell lung cancer with EGFR Ex20ins mutations. Patients who had experienced disease progression on platinum-based chemotherapy were enrolled in the study. The study demonstrated the effectiveness of amivantamab in treating advanced NSCLC with EGFR Ex20ins mutations across diverse patient groups and […]
PSCA-Targeted CAR T Cells Show Promise in mCRPC Patients
The phase I trial aimed to evaluate the safety and efficacy of PSCA-targeted 4-1BB-co-stimulated CAR T cell therapy in patients with mCRPC. CAR T cells were manufactured and infused into patients with disease progression after at least 1 androgen receptor-targeted therapy. The study found that PSCA-CAR T cells can potentially treat mCRPC, but […]
CheckMate 214 Study: Clinical Efficacy of NIVO+IPI in sRCC Patients
Phase 3 of CheckMate 214 trial was conducted to study the long-term efficacy and suitability of NIVO+IPI as a 1L treatment for patients with Untreated Advanced or Metastatic Renal Cell Carcinoma with Sarcomatoid features. 139 patients were randomized in an open-label trial to compare the NIVO+IPI combination with SUN monotherapy, where NIVO+IPI proved […]
ctDNA Testing in mCRPC Patients with HRR Gene Alterations
The phase 3 PROfound study included patients with mCRPC whose plasma samples were retrospectively sequenced using circulating tumor DNA (ctDNA) Next-Generation Sequencing (NGS) to test for BRCA/ATM alterations. The efficacy of Olaparib was consistent, irrespective of the method used to identify the BRCA/ATM alterations. The study demonstrated that ctDNA NGS might be used […]
Enrolling Trials
Sign up for our emails
Trusted insights straight to your inbox and get the latest updates from OncWeekly
Newsletter
Privacy Policy
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
SELECT ONCOLOGY JOURNAL ARTICLES
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS >=1%: results from a multicenter, open-label, phase 2 trial
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus famitinib (a receptor tyrosine kinase …
Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Correction: PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4+ naïve T cells at baseline are associated with severe immune-related adverse events in immune checkpoint inhibitor-treated melanoma
Background Immune-related adverse events (irAEs) are major barriers of clinical management and further development of immune checkpoint inhibitors (ICIs) for cancer therapy. Therefore, biomarkers associated with the onset of severe irAEs are needed. In this study, …
1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
Background Squamous non-small cell lung cancer (SQ-NSCLC) is the 2nd most common type of lung cancer. Given the paucity of actionable oncogene drivers, and lack of efficacy from multiple therapies in the Lung-MAP trial, there is …